Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies
about
Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapyAdvancements in the delivery of epigenetic drugsIntegrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implicationsA systems biology approach to invasive behavior: comparing cancer metastasis and suburban sprawl developmentPhase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II reportPrognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.Oxidative stress and DNA methylation in prostate cancer.A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancerDNA methylation of cancer genome.A semantic web framework to integrate cancer omics data with biological knowledge.Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.The role of azacitidine in the management of myelodysplastic syndromes (MDS).Aberrant DNA methylation in malignant melanomaThe novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.Demethylating agents in myeloid malignancies.The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromesDownregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells.Epigenetics in breast and prostate cancerPhase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyChromatin-targeting small molecules cause class-specific transcriptional changes in pancreatic endocrine cells.Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.MTRR silencing inhibits growth and cisplatin resistance of ovarian carcinoma via inducing apoptosis and reducing autophagy.Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cellsEpigenetic resensitization to platinum in ovarian cancerEpigenetic changes in gliomas.New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.HLA-G regulators in cancer medicine: an outline of key requirements.Mechanistic insights into epigenetic modulation of ethanol consumption.Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells.5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells.Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.
P2860
Q27027093-821D4C3F-B16E-4B3D-983E-829ED8B90FFDQ28088478-FBF34BF8-BC1E-41B0-B463-A4E9B0087B0FQ28474843-3AECA8AB-DC40-4E21-9E85-5E55EACE5DFAQ33533975-8D249B5D-294F-45B2-9937-24C6EC758F80Q33658203-53C1B5CF-92CD-4F1F-B38B-53D41A52141DQ33665187-9464E6C3-A659-4956-A52E-D33796AC6161Q33744733-E7264439-0B12-40B2-8640-791AFE80A179Q33903052-DE468EEB-C480-453A-9C1B-FF9C3AB0900AQ34021985-F87E8A99-376B-4AE6-9DFA-50E85F8D29CCQ34091420-3AB14E2E-43C3-4EF6-B12E-2ADFD2EAD1D3Q34133706-E78336D7-67EA-4387-B19E-ECDC62106FA3Q34176647-8A9DD699-E6B0-4522-863F-C1039C7CCA37Q34345218-236D7356-5E24-47BA-8C51-E097D14C1F66Q34418429-BF311D14-5B2F-4EF8-A0E2-28384DF47C0FQ34516587-DB31A557-88B0-443E-98C4-E0B027B0CC33Q34717933-263A314C-B6CE-4860-9A05-12FA59CA93F1Q34847863-A93FAEDF-B996-47CB-A087-C97D5A786F7CQ34979774-B3F0F414-3198-4BF8-97F9-9F0F83CD820AQ35051937-30EBFE5A-7220-4CC6-9D00-5B0CC3B54F45Q35136616-1A724E38-35CC-41C3-BA6F-7196A3757F34Q35169101-E9B51A98-3B0A-464A-BEFE-90B3705068AEQ35190483-EA1003D4-99F8-4601-93CF-E3AF203E3B3FQ35628323-7652A988-8588-4043-AD93-9EC387C6826DQ35739684-AFC88D6F-D7B2-4154-9F43-2A1468DCB9F6Q35794439-F1397916-9D09-4080-AE35-A3F04560E0AEQ35887221-E574EC7F-5D11-4F13-BC46-27749E50CF88Q36203084-55F059A3-FD68-4EAF-97FB-936F2BC2F61DQ36225822-F58549CD-4367-4FC7-8888-04A73C9D64F5Q36609590-A9A9C4E2-6B77-454B-BB0E-0B1F03A7A5B6Q36972667-2FB62FC0-160A-42A2-99D9-5A514C603E6EQ36979382-999301A6-F73D-4B25-AC51-35A1068FD619Q37287032-CDAA235D-A627-4ECC-8E03-40B58E36C090Q37503780-EF6FE833-437A-4EAA-A7D8-EE8AFD925324Q37906387-96444E2E-3DC8-4E23-9484-C05941DBFF50Q38825067-837D10A8-5392-40D8-925D-BFF28D22069AQ39029463-CE3D93DA-7E80-436C-B916-3C2FE4046548Q39241889-3B24B1A3-6D7C-4399-B149-BAC26CCFBA52Q39381251-C6E3AFF4-DC6E-4344-9CD0-D0EE316252BFQ39566623-25CC4AF3-A284-4C21-BA92-541E43AA12CAQ39620587-0606035B-BED9-47C3-A009-4A57E1856A87
P2860
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Evolution of decitabine develo ...... gations, and future strategies
@ast
Evolution of decitabine develo ...... gations, and future strategies
@en
Evolution of decitabine develo ...... gations, and future strategies
@nl
type
label
Evolution of decitabine develo ...... gations, and future strategies
@ast
Evolution of decitabine develo ...... gations, and future strategies
@en
Evolution of decitabine develo ...... gations, and future strategies
@nl
prefLabel
Evolution of decitabine develo ...... gations, and future strategies
@ast
Evolution of decitabine develo ...... gations, and future strategies
@en
Evolution of decitabine develo ...... gations, and future strategies
@nl
P2860
P50
P356
P1433
P1476
Evolution of decitabine develo ...... gations, and future strategies
@en
P2093
Jean-Pierre Issa
P2860
P304
P356
10.1002/CNCR.23463
P407
P577
2008-06-01T00:00:00Z